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DNA damage can arrest replication forks during S phase. Failure to stabilize and restart arrested forks results
in fork collapse and genomic instability. In this issue of Cancer Cell, Schlacher et al. show that the Fanconi
anemia and BRCA2 tumor suppressor pathways cooperate to protect stalled replication forks from
degradation.Patients with the rare genetic disorder
Fanconi anemia (FA) exhibit increased
cancer susceptibility, anemia, and devel-
opmental malformations (Crossan and
Patel, 2012). The fifteen FA genes coop-
erate in a genome stability pathway that
is essential for tolerance and repair of
DNA crosslinks. Cells derived from FA
patients are hypersensitive to DNA cross-
linking agents and exhibit DNA damage
checkpoint and mitosis defects. Monou-
biquitination of the FA proteins FANCD2
and FANCI by a ubiquitin ligase complex,
termed the FA core complex, is an essen-
tial step in the pathway and leads to the
formation of active repair complexes on
chromatin; thus, FANCD2 monoubiquiti-
nation is a biomarker of FA pathway acti-
vation. The FA pathway is activated not
only by DNA crosslinks but also by
treatment with other replication stalling
agents, such as hydroxyurea (HU) or UV
light. Paradoxically, FA patient cells are
hypersensitive to crosslinks, but not these
latter agents. The function of the FA
pathway in the context of replication fork
activity has remained elusive. In this issue
of Cancer Cell, Schlacher et al. (2012)
demonstrate that the FA pathway is
required to stabilize stalled replication
forks and protect them from nucleolytic
degradation, thus suppressing genomic
instability and tumorigenesis.
These investigators previously exam-
ined the function of the breast cancer
susceptibility factor BRCA2 in replication
fork protection (Schlacher et al., 2011).
BRCA2 is known to function as amediator
of homologous recombination (HR) by
inhibiting the ATPase activity of RAD51
and by catalyzing the formation of RAD51
nucleofilaments at processed double
strand breaks (Heyer et al., 2010). By em-ploying single DNA fiber analysis, the
authors previously showed that BRCA2
is also required for the stabilization of
stalled replication forks. BRCA2 achieves
this function by promoting RAD51 nucleo-
filament formation at stalled forks; RAD51
coating confers protection against DNA
degradation by the nuclease MRE11
(Schlacher et al., 2011).
In the current work, the authors extend
these studies by examining the FANCD2
protein. Many genetic and biochemical
findings connect the FA and HR path-
ways. FANCD2 and BRCA2 interact and
co-localize in DNA damage-induced foci
(Hussain et al., 2004). Several HR pro-
teins, including BRCA2 itself, are encoded
by FA genes that are inactivated through
biallelic germline mutations in FA patients
(Howlett et al., 2002; Walsh and King,
2007). These links, as well as the above-
mentioned activation of the FA pathway
by replication stalling agents such as
HU and UV light, prompted the authors
to investigate if FANCD2 and the FA
core complex proteins are also required
for promoting replication fork stability.
Perhaps not surprisingly, they found that
FA pathway deficient cells have a dra-
matic shortening of the nascent strand
following replication fork stalling in-
duced by HU treatment. This defect was
associated with an increase in chro-
mosomal aberrations observed in meta-
phase spreads, suggesting that the FA
pathway protects stalled replication forks
from degradation and thereby prevents
genomic instability and transformation.
Similar to BRCA2, FANCD2 promotes
RAD51nucleofilament formation at stalled
forks and thereby prevents cleavage by
the MRE11 nuclease (Figure 1). Impor-
tantly, the authors show that FANCD2,Cancer CBRCA2, and RAD51 are epistatic in repli-
cation fork stabilization. These studies
represent the most convincing functional
data, so far, confirming that the upstream
FA proteins and BRCA2/FANCD1 partici-
pate in a common pathway for tumor sup-
pression, termed the FA/BRCA pathway.
Perhaps the most thought-provoking
finding of this work is that gain of RAD51
function, by either expressing a mutant
RAD51 that forms hyper-stable RAD51
filaments or overexpressing the wild-type
RAD51, can compensate for FANCD2
deficiency. Overexpression rescues the
length of the nascent replication tract in
FANCD2-defective cells. This result sug-
gests that promoting RAD51 accumula-
tion at stalled replication forks is enough
to alleviate the fork stabilization defect
caused by FA/BRCA pathway mutations
(Figure 1C).
It is unclear whether RAD51 overex-
pression also suppresses the sponta-
neous or DNA damage-induced chromo-
somal aberrations seen in FA patients.
It will also be important to determine
whether hyperactive RAD51 can alleviate
the anemia phenotype that FA deficiency
confers to organisms. The molecular
mechanism that induces stem cell deple-
tion in FA patients remains unclear. It is
conceivable that this novel function of
the FA pathway in protecting stalled repli-
cation forks against degradation is impor-
tant for the maintenance and functionality
of hematopoietic stem cells. Thus, the
work of Schlacher et al. (2012) opens
up the possibility for new therapeutic
avenues for FA patients. The chemical
compound RS-1 is known to promote
the formation of RAD51 nucleofilaments
(Jayathilaka et al., 2008). It will be inter-
esting to investigate if this compoundell 22, July 10, 2012 ª2012 Elsevier Inc. 5
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Figure 1. The Fanconi Anemia Pathway and BRCA2 Cooperate to Promote the Stability of Stalled Replication Forks
(A) FA proteins and BRCA2 protect stalled replication forks against degradation by stabilizing RAD51 filaments.
(B) In the absence of the FA/BRCA pathway, the MRE11 nuclease degrades stalled replication forks, promoting genomic instability.
(C) Fork protection in FA/BRCA pathway mutants can be rescued by stabilizing RAD51 filaments. RAD51 is represented by red dots.
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Previewscan suppress the phenotypes of FA
cells and patients. Moreover, the PARI
protein was shown to disrupt the interac-
tion between RAD51 and single stranded
DNA, thus suppressing hyper-recombina-
tion (Moldovan et al., 2012). However, it is
not clear if PARI can disrupt RAD51 repli-
cation fork filaments. Interestingly, PARI
interacts with the replication protein
PCNA, a master regulator of replication-
coupled DNA repair processes. It is there-
fore possible that PARI may play a role in
regulating replication fork stability by
controlling RAD51 levels at stalled repli-
cation forks. PARI inhibition may result
in stabilizing RAD51 at such structures,
thereby representing yet another ap-
proach for FA therapy. Indeed, PARI
depletion was shown to improve genomic
stability of BRCA2- and FANCJ-deficient
cells.
On the other hand, it is important
to note that RAD51 is overexpressed
in numerous tumor types (Klein, 2008).
RAD51 overexpression in tumors is as-
sociated with resistance to genotoxic
therapy. In model systems, RAD51 over-
expression promotes toxic or deleterious
recombination and genomic instability.
Therefore, a delicate equilibrium between
the different consequences of RAD51
hyper-activation must be achieved for6 Cancer Cell 22, July 10, 2012 ª2012 Elsevisuch treatment strategies to succeed
(Heyer et al., 2010).
By identifying this novel role of FA
proteins, Schlacher et al. (2012) provide
important insights into the mechanism of
BRCA2-dependent fork stabilization. Still,
several questions remain unanswered.
Most importantly, how are stalled replica-
tion forks, which are covered by RAD51,
ultimately repaired and restarted? HR
may not be involved. Based on recent
work in the FA field, FA proteins may
recruit DNA polymerases to restart the
fork and may recruit SLX4, a landing
pad for nuclease activity, to process the
fork. The poorly characterized template
switching mechanism that requires
multi-ubiquitination of PCNA at stalled
forks may also be involved. DNA fiber
assays following depletion of the factors
involved in these processes should shed
light on the pathway involved. Also
intriguing is the involvement of MRE11;
how this specific nuclease degrades
stalled replication forks in the absence of
RAD51 filaments is unclear. Are there
other nucleases involved?
Although initially identified 85 years
ago, FA remains a fatal genetic dis-
ease. The addition of yet another activity,
namely the protection of stalled replica-
tion forks against nucleolysis, furtherer Inc.underscores the multifaceted role of the
FA pathway as an essential barrier against
genomic instability and cancer.REFERENCES
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